Activity of host antimicrobials against multidrug-resistant acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2972-2975

  García Quintanilla, Meritxell ^a   Pulido, Marina R ^a   Moreno Martínez, Patricia ^a   Martín Peña, Reyes ^a   López Rojas, Rafael ^a   Pachón, Jerónimo ^a   McConnell, Michael J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; COLISTIN; LIPOPOLYSACCHARIDE; LYSOZYME; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; HOST; NONHUMAN; PRIORITY JOURNAL; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ANTI-INFECTIVE AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; LIPOPOLYSACCHARIDES; MICROBIAL SENSITIVITY TESTS;

EID: 84898636349     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02642-13     Document Type: Article

References (23)

1. López-Rójas R, Jiménez-Mejías ME, Lepe JA, Pachón J. 2011. Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain. J. Infect. Dis. 204:1147-1148. http://dx.doi.org/10.1093/infdis/jir476.
2. Taccone FS, Rodríguez-Villalobos H, De Backer D, De Moor V, Deviere J, Vincent JL, Jacobs F. 2006. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur. J. Clin. Microbiol. Infect. Dis. 25:257-260. http://dx.doi.org/10.1007/s10096-006-0123-1.
3. Valencia R, Arroyo LA, Conde M, Aldana JM, Torres MJ, Fernández-Cuenca F, Garnacho-Montero J, Cisneros JM, Ortiz C, Pachón J, Aznar J. 2009. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect. Control Hosp. Epidemiol. 30:257-263. http://dx.doi.org/10. 1086/595977.
4. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA. 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53:3628-3634. http://dx.doi.org/10.1128/AAC.00284-09.
5. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM, Woodford N. 2011. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the PmrAB two-component regulatory system. Antimicrob. Agents Chemother. 55:3370-3379. http://dx.doi.org/10.1128/AAC.00079-11.
6. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. 2011. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob. Agents Chemother. 55:3022-3024. http://dx.doi.org/10.1128/AAC.01732-10.
7. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St. Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD. 2010. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54:4971-4977. http://dx.doi.org/10.1128/AAC.008 34-10.
8. Vandamme D, Landuyt B, Luyten W, Schoofs L. 2012. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell. Immunol. 280:22-35. http://dx.doi.org/10.1016/j.cellimm.2012.11.009.
9. Moffatt JH, Harper M, Mansell A, Crane B, Fitzsimons TC, Nation RL, Li J, Adler B, Boyce JD. 2013. Lipopolysaccharide-deficient Acinetobacter baumannii shows altered signaling through host Toll-like receptors and increased susceptibility to the host antimicrobial peptide LL-37. Infect. Immun. 81:684-689. http://dx.doi.org/10.1128/IAI.01362-12.
10. Napier BA, Burd EM, Satola SW, Cagle SM, Ray SM, McGann P, Pohl J, Lesho EP, Weiss DS. 2013. Clinical use of colistin induces crossresistance to host antimicrobials in Acinetobacter baumannii. mBio 4(3): e00021-00013. http://dx.doi.org/10.1128/mBio.00021-13.
11. Callewaert L, Van Herreweghe JM, Vanderkelen L, Leysen S, Voet A, Michiels CW. 2012. Guards of the great wall: bacterial lysozyme inhibitors. Trends Microbiol. 20:501-510. http://dx.doi.org/10.1016/j.tim.2012.06.005.
12. During K, Porsch P, Mahn A, Brinkmann O, Gieffers W. 1999. The non-enzymatic microbicidal activity of lysozymes. FEBS Lett. 449:93-100. http://dx.doi.org/10.1016/S0014-5793(99)00405-6.
13. Ibrahim HR, Thomas U, Pellegrini A. 2001. A helix-loop-helix peptide at the upper lip of the active site cleft of lysozyme confers potent antimicrobial activity with membrane permeabilization action. J. Biol. Chem. 276: 43767-43774. http://dx.doi.org/10.1074/jbc.M106317200.
14. Fernández-Cuenca F, Pascual A, Ribera A, Vila J, Bou G, Cisneros JM, Rodríguez-Baño J, Pachón J, Martínez- Martínez L. 2004. Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000). Enferm. Infecc. Microbiol. Clin. 22:267-271. (In Spanish.
15. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. CLSI, Wayne, PA.
16. Fernández-Reyes M, Rodríguez-Falcon M, Chiva C, Pachón J, Andreu D, Rivas L. 2009. The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. Proteomics 9:1632-1645. http://dx.doi.org/10.1002/pmic.200800434.
17. Schaub IG, Hauber FD. 1948. A biochemical and serological study of a group of identical unidentifiable Gram-negative bacilli from human sources. J. Bacteriol. 56:379-385.
18. Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE. 2008. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 76:4176-4182. http://dx.doi.org/10.1128/IAI.00318-08.
19. Sorensen O, Cowland JB, Askaa J, Borregaard N. 1997. An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J. Immunol. Methods 206:53-59. http://dx.doi.org/10.1016/S0022-1759 (97)00084-7.
20. Cole AM, Liao HI, Stuchlik O, Tilan J, Pohl J, Ganz T. 2002. Cationic polypeptides are required for antibacterial activity of human airway fluid. J. Immunol. 169:6985-6991.
21. Sochacki KA, Barns KJ, Bucki R, Weisshaar JC. 2011. Real-time attack on single Escherichia coli cells by the human antimicrobial peptide LL-37. Proc. Natl. Acad. Sci. U. S. A. 108:E77-E81. http://dx.doi.org/10.1073/pnas. 1101130108.
22. Durr UH, Sudheendra US, Ramamoorthy A. 2006. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim. Biophys. Acta 1758:1408-1425. http://dx.doi.org/10.1016/j.bbamem.2006.03.030.
23. Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, Bonomo RA, Fernández L, Hancock RE, Adams MD, French SW, Buslon VS, Spellberg B. 2012. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. mBio 3(5): e00312-12. http://dx.doi.org/10.1128/mBio. 00312-12.